Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis

被引:18
作者
Kaji, Hiroshi [1 ]
Hisa, Itoko [1 ]
Inoue, Yoshifumi [1 ]
Naito, Junko [1 ]
Sugimoto, Toshitsugu [2 ]
Kasuga, Masato [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Endocrinol Diabet & Metab,Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Shimane Univ, Fac Med, Matsue, Shimane, Japan
关键词
Osteoporosis; Bisphosphonate; Bone mineral density; Glucose; Body composition; FRACTURE INTERVENTION TRIAL; TYPE-2; DIABETES-MELLITUS; PARATHYROID-HORMONE; VITAMIN-D; VERTEBRAL FRACTURES; METABOLIC SYNDROME; WOMEN; RISK; ALENDRONATE; RISEDRONATE;
D O I
10.1007/s00774-008-0005-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bisphosphonate is an effective drug to reduce fracture risk in osteoporotic patients; however, factors affecting the efficacy of bisphosphonate treatment are not fully known, especially in Japanese patients. In the present study, we examined the relationships between an increase in lumbar spine bone mineral density (BMD) by bisphosphonates and several pretreatment parameters, including biochemical, bone/mineral, and body composition indices, in 85 postmenopausal osteoporotic patients treated with alendronate or risedronate. BMD increase was measured by dual-energy X-ray absorptiometry at the lumbar spine before and 2 years after treatment. BMD increase at the lumbar spine was observed as independent of age, height, weight, body mass index, and fat mass, although lean body mass seemed slightly related. On the other hand, fasting plasma glucose (FPG) levels were significantly and positively related to BMD increase at the lumbar spine. In multiple regression analysis, FPG levels were not significantly related to BMD increase at the lumbar spine when lean body mass was considered. As for bone/mineral parameters, BMD increase at the lumbar spine was not significantly related to serum levels of calcium, parathyroid hormone (PTH), and alkaline phosphatase or urinary levels of deoxypiridinoline and calcium excretion. As for BMD parameters, Z-scores of BMD at any site and bone geometry parameters obtained by forearm peripheral quantitative computed tomography were not significantly related to BMD increase at the lumbar spine. BMD increases at the lumbar spine were similar between groups with or without vertebral fractures. In conclusion, BMD increase at the lumbar spine by bisphosphonate treatment was not related to any pretreatment parameters, including body size, body composition, and bone/mineral metabolism in postmenopausal Japanese women with primary osteoporosis, although FPG correlated partly to BMD through lean body mass.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 35 条
[1]   Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial [J].
Bauer, DC ;
Garnero, P ;
Hochberg, MC ;
Santora, A ;
Delmas, P ;
Ewing, SK ;
Black, DM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (02) :292-299
[2]   Risk of fracture in women with type 2 diabetes: The Women's Health Initiative Observational Study [J].
Bonds, Denise E. ;
Larson, Joseph C. ;
Schwartz, Ann V. ;
Strotmeyer, Elsa S. ;
Robbins, John ;
Rodriguez, Beatriz L. ;
Johnson, Karen C. ;
Margolis, Karen L. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (09) :3404-3410
[3]   INFLUENCE OF AGE, SEX, AND INSULIN ON OSTEOBLAST FUNCTION - OSTEOBLAST DYSFUNCTION IN DIABETES-MELLITUS [J].
BOUILLON, R ;
BEX, M ;
VANHERCK, E ;
LAUREYS, J ;
DOOMS, L ;
LESAFFRE, E ;
RAVUSSIN, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (04) :1194-1202
[4]   Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects [J].
Chen, QX ;
Kaji, H ;
Iu, MF ;
Nomura, R ;
Sowa, H ;
Yamauchi, M ;
Tsukamoto, T ;
Sugimoto, T ;
Chihara, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10) :4655-4658
[5]   Meta-analysis of alendronate for the treatment of postmenopausal women [J].
Cranney, A ;
Wells, G ;
Willan, A ;
Griffith, L ;
Zytaruk, N ;
Robinson, V ;
Black, D ;
Adachi, J ;
Shea, B ;
Tugwell, P ;
Guyatt, G .
ENDOCRINE REVIEWS, 2002, 23 (04) :508-516
[6]   Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis [J].
Cranney, A ;
Tugwell, P ;
Adachi, J ;
Weaver, B ;
Zytaruk, N ;
Papaioannou, A ;
Robinson, V ;
Shea, B ;
Wells, G ;
Guyatt, G .
ENDOCRINE REVIEWS, 2002, 23 (04) :517-523
[7]   Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial [J].
Cummings, SR ;
Black, DM ;
Thompson, DE ;
Applegate, WB ;
Barrett-Connor, E ;
Musliner, TA ;
Palermo, L ;
Prineas, R ;
Rubin, SM ;
Scott, JC ;
Vogt, T ;
Wallace, R ;
Yates, AJ ;
LaCroix, AZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24) :2077-2082
[8]   Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. [J].
de Liefde, II ;
van der Klift, M ;
de Laet, CEDH ;
van Daele, PLA ;
Hofman, A ;
Pols, HAP .
OSTEOPOROSIS INTERNATIONAL, 2005, 16 (12) :1713-1720
[9]   Type 2 diabetes mellitus in nursing home patients:: Effects on bone turnover, bone mass, and fracture risk [J].
Dobnig, Harald ;
Piswanger-Soelkner, Jutta Claudia ;
Roth, Martin ;
Obermayer-Pietsch, Barbara ;
Tiran, Andreas ;
Strele, Andrea ;
Maier, Elisabeth ;
Maritschnegg, Peter ;
Sieberer, Christian ;
Fahrleitner-Pammer, Astrid .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (09) :3355-3363
[10]   Body size and hip fracture risk in older women: A prospective study [J].
Ensrud, KE ;
Lipschutz, RC ;
Cauley, JA ;
Seeley, D ;
Nevitt, MC ;
Scott, J ;
Orwoll, ES ;
Genant, HK ;
Cummings, SR .
AMERICAN JOURNAL OF MEDICINE, 1997, 103 (04) :274-280